drug
CID-103
Phase 2updated 3mo agoby $CASIF CASI Pharmaceuticals, Inc.
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying CID-103
- phase2A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
- phase2A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
- phase1CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that